Cannabidiol (CBD) is a phytocannabinoid discovered in It is one of some identified .. Canada. On October 17, , cannabidiol became legal for recreational and medical use. While we are definitely moving in the right direction, the legality of CBD as a whole is still very unclear due to different laws in different states. CBD oil has exploded in popularity lately. While only 9 states currently have legalized recreational marijuana, as an industry weed has had a huge year of growth. But because marijuana legalization is in such a murky situation with both federal and state laws to grapple with, CBD.
Retrieved December 10, Retrieved 14 May National Conference of State Legislatures. Retrieved 13 January Retrieved 6 November Retrieved January 3, The Farm Bill. Retrieved January 29, Retrieved December 4, Retrieved June 2, Retrieved 19 October Retrieved 1 January Retrieved 1 February Annales de Toxicologie Analytique in French. Swedish Medical Products Agency. Retrieved 31 July BBC News - Health. Retrieved 8 February Retrieved May 20, Is Cannabidiol the Answer for Disorders of Motivation?
Annual Review of Neuroscience. Williams, Alex October 27, The New York Times. Articles related to Cannabidiol. Recreational and medical applications rights Industrial applications. Autoflowering cannabis Cannabis indica ruderalis sativa Difference between C. Medical cannabis History Timeline Religious and spiritual use Chalice. Cannabis in pregnancy Dependence Effects of cannabis Long-term Endocannabinoid system Impaired driving.
Adult lifetime use by country Annual use by country. Return to class B Uruguay: Decriminalization of non-medical use Rescheduling per the Controlled Substances Act.
Cannabis political parties List of British politicians who have acknowledged cannabis use List of American politicians who have acknowledged cannabis use. ADPF Gonzales v. United States thermal imaging Leary v. Cannabis portal Hemp portal Category. Cannabinoid receptor modulators cannabinoids by pharmacology List of: Analgesics N02A , N02B.
Meclofenamic acid Mefenamic acid. Cannabidiol Cannabis Nabilone Nabiximols Tetrahydrocannabinol dronabinol. Gabapentin Gabapentin enacarbil Pregabalin Ziconotide.
Carbamazepine Lacosamide Local anesthetics e. Bromide potassium bromide , sodium bromide Imepitoin Paraldehyde Stiripentol. Fatty acids and related: Valproate Valpromide Valproate pivoxil Vigabatrin. Progabide ; GAT-1 inhibitors: Ethotoin Fosphenytoin Mephenytoin Phenytoin ; Ureides: Valproate Valpromide Valproate pivoxil ; Carboxamides: Carbamazepine Eslicarbazepine acetate Oxcarbazepine ; Others: Lacosamide Lamotrigine Rufinamide Topiramate Zonisamide. Cases addressing hemp, which both preceded and succeeded this ruling, do not resolve the issue.
In contrast, cannabis-derived CBD products can only be purchased by qualifying patients in states with medical cannabis laws 31 states, and the District of Columbia as of this writing or by customers in states with recreational cannabis laws 9 and the District of Columbia as of this writing. This preclusion is not entirely novel. In a somewhat similar case, Biostratum, a pharmaceutical company, requested the FDA to take action against manufacturers of pyridoxamine-containing dietary supplements because Biostratum had submitted an IND application for pyridoxamine dihydrochloride.
Products containing pyridoxamine and being sold as dietary supplements are not currently permitted. There is another precedent that informs predictions of how the FDA might approach the sales and marketing of hemp-derived CBD products in the post-Epidiolex era. In April , Pharmanex, a dietary supplement manufacturer, was advised by the FDA that its mevinolin-containing dietary supplement, named Cholestin, was a drug, not a dietary supplement. Mevinolin, also known as monocalin K, is a constituent of red yeast rice and has been shown to lower elevated cholesterol levels.
The FDA concluded that Cholestin was manufactured to contain concentrations of lovastatin that exceeded traditional red yeast rice products, and the product was thus more similar to a drug than any red yeast rice product available OTC.
Many red yeast rice products remain on the market. In the Cholestin case, the FDA's argument hinged on the concentration of lovastatin in red yeast rice products exceeding some traditional standard. It is worth noting that the FDA is a public health agency with a myriad of competing priorities and a limited enforcement budget.
When considering an enforcement action, the FDA weighs multiple factors, including benefits and harms. It is plausible that the FDA will choose not to exercise its enforcement options. Myriad factors contribute to this complexity, including convoluted and conflicting regulations at both the federal and state levels, court rulings that have failed to achieve resolution, confusion relating to the definitions of cannabis and hemp, pending legislation, and the FDA's position on CBD as a drug and not a dietary supplement ingredient.
Although the implications of these complexities are widespread, restrictions in clinical research, in particular, have hindered the understanding of important safety and efficacy considerations. As a result, individuals are currently using CBD products to treat medical conditions without the support of informed healthcare providers.
Increased enforcement could result in decreased access. In contrast, passage of the Hemp Bill, which expressly legalizes hemp-derived cannabinoids, including CBD, may prevent enforcement by creating a de facto legal market for hemp-derived CBD products that is separate and distinct from the medical market for Epidiolex. Or, perhaps products with low concentrations of CBD will remain below FDA enforcement priorities, as in the case of red yeast rice. CBD is currently lawful under certain conditions if derived from a lawful source.
Cite this article as: National Center for Biotechnology Information , U. Journal List Cannabis Cannabinoid Res v. Published online Sep Find articles by Jamie Corroon. Find articles by Rod Kight. In this post, I hope to shed some light on the legal status of cannabidiol CBD under federal law. Let me elaborate on each of these three circumstances, which, for reasons that will become clear, appear vanishingly narrow.
As discussed in my book page 21 , Congress defined marijuana to include:. Such term does not include the mature stalks of such plant, fiber produced from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mixture, or preparation of such mature stalks except the resin extracted therefrom , fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination.
Because Congress excluded certain parts of the cannabis plant e. Drug Enforcement Administration , F. For example, the Rule would have effectively forbidden the sale or even possession of a variety of innocuous products, like textiles, made from the mature stalks etc.
The full Rule and comments to it can be found here. In a non-published decision, Hemp Industries Association v. Drug Enforcement Administration , Fed.
Marijuana Law, Policy, and Authority
But while many reports are claiming that this means that cannabidiol (CBD) is also legal, that's not quite correct. With a lot of misinformation. While we don't have all the answers, we'll try to explain Cannabidiol's current legal status as best we can. We'll also discuss a few things about the future legality. In recent months, cannabidiol, or CBD—the non-psychotropic chemical compound that occurs naturally in cannabis—has become increasingly.